Table 3.
Compilation of studies examining the additive interactions between Epstein-Barr virus and overweight/obesity in relation to the development of MS.
| Risk factors | OR for each risk factor in the absence of the other/s | Combined OR | Additive interaction |
Reference |
|---|---|---|---|---|
| Anti-EBNA 50-75th percentile* Adolescent BMI>25 kg/m2 |
2.1 + 1.5 | 2.7 | AP 0.02 (-0.3-0.3) | 151 |
| Anti-EBNA 75-95th percentile* Adolescent BMI>25 kg/m2 |
3.4 + 1.4 | 4.6 | AP 0.3 (0.1-0.5) | 151 |
| Anti-EBNA >95th percentile * Adolescent BMI>25 kg/m2 |
4.0 + 1.4 | 7.3 | AP 0.4 (0.1-0.7) | 151 |
| Anti-EBNA>median HLA-DRB1*15:01 positive Adolescent BMI>25 kg/m2 |
2.5 + 2.8 + 1.6 | 13.5 | Total RERI 8.6 (5.0-12.1) | 151 |
| Past IM Adolescent BMI>27 kg/m2 |
1.8 + 1.7 | 8.1 | AP 0.7 (0.3-0.8) RERI 5.5 (1.7-12.8) SI 4.6 (2.0-10.2) |
152 |
| Past IM Adolescent BMI>27 kg/m2 |
1.8 + 1.6 | 7.0 | 0.7 (0.2-0.8) RERI 4.5 (1.1-11.2) SI 4.2 (1.7-10.2) |
152 |
| Past IM DRB1*1501 positive Adolescent BMI>25 kg/m2 |
2.0 + 3.4 + 1.4 | 22.2 | Total RERI 15.4 (0.8-30.1) | 151 |
*Reference group was EBNA-1 antibody levels below the median among controls; OR, odds ratio; EBNA, Epstein-Barr virus nuclear antigen; IM, infectious mononucleosis; BMI, body mass index; AP, attributable proportion due to interaction; RERI, relative excess risk due to interaction; SI, synergy index.
The total 3-way interaction takes all two-way interactions and the three-way interaction into account.